rightteens.blogg.se - Alpha medical

ALPHA MEDICAL SKIN
ALPHA MEDICAL SERIES

For more information, please see the publication here.

ALPHA MEDICAL SKIN

multicenter pilot trial in skin cancer were published in JAMA Network Open, showing a 100% Complete Response rate at 12 weeks post treatment and no device-related serious adverse events or systemic toxicity reported. In May, the results of the Company’s U.S.

For more information, please refer to NCT05829291.

In March, the Company received Health Canada approval to open a liver cancer feasibility trial.

For more information, please refer to NCT04002479.

In April, the first patient with advanced inoperable pancreatic cancer was treated in a feasibility and safety study of Alpha DaRT at the Jewish General Hospital in Montreal, Canada, which is an affiliated teaching hospital of McGill University, Faculty of Medicine.

For more information, please refer to NCT05323253. multicenter pivotal ReSTART trial in recurrent squamous cell carcinoma which remains on track.

In March, the Company initiated and treated the first patients in its U.S.

Alpha Tau remains adequately capitalized to support all of these programs over the coming years," he concluded. In parallel, we are preparing for potential future product launches by advancing our commercial planning activities and solidifying our supply chain. marketing authorizations in other indications. "Read-outs from the pivotal trial and these smaller feasibility programs should represent meaningful inflection points for our growth story and could pave the way for larger studies that may support potential U.S.

ALPHA MEDICAL SERIES

multicenter pivotal trial in recurrent cutaneous squamous cell carcinoma, which is expected to produce data in 2024, and on initiating a series of feasibility trials in difficult-to-treat internal organ tumors with high unmet need, such as pancreatic and liver cancers,” stated Alpha Tau CEO Uzi Sofer. "This year we are focused on advancing our ReSTART U.S. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported first quarter 2023 financial results and provided a corporate update. JERUSALEM, (GLOBE NEWSWIRE) - Alpha Tau Medical Ltd. Cash, cash equivalents & deposits balance of $ 100.5 million with runway of at least two years.

Received Health Canada approval in March to initiate a liver cancer feasibility tria l, with recruitment targeted to begin mid-year. Treated the first patient with squamous cell carcinoma of the vulva in a safety and feasibility in the UK in May. multicenter pilot trial in skin cancer published in JAMA Network Open in May.

Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in April. multicenter pivotal trial in recurrent cutaneous skin cancer, which began enrolling patient s in March.